A
Aikelian Biotechnology
Next-generation T-cell engager immunotherapies for solid tumors.
About Aikelian Biotechnology
Aikelian Biotechnology, operating as Excalipoint Therapeutics, is a clinical-stage biotechnology company developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases. The company was established in Shanghai, China, in August 2025, operating under a “NewCo” model that integrates experienced founders, venture capital, and pipeline assets to accelerate drug development.
Excalipoint was co-founded by CEO Dr. Lei Fang and CFO/CBO Jielun Zhu. Dr. Fang has a background in immunology and T-cell biology, with previous leadership roles at Lepu Biopharma and I-Mab Biopharma. Mr. Zhu contributes over 20 years of experience in healthcare and capital markets. The company launched with an oversubscribed seed financing of $68.7 million, one of the largest for a Chinese biotech startup. This included an initial $41 million at its inception and a $27.7 million extension six months later. The funding round was supported by a syndicate of top-tier investors, including HSG, Apricot Capital, Yuanbio Venture Capital, Lilly Asia Ventures, and Eisai's venture arm, Eisai Innovation.
The company's business model is focused on developing a portfolio of antibody drugs and proprietary platforms to overcome the limitations of existing TCE therapies, particularly in treating solid tumors. Excalipoint is developing three main technology platforms: TOPAbody, T-Cell Immune Shield, and TCE Probody. These platforms are designed to enhance the efficacy and safety of immunotherapies by addressing challenges such as converting immunologically "cold" tumors to "hot" ones and mitigating the immunosuppressive tumor microenvironment. The company's pipeline consists of six differentiated programs. Its lead candidate, EXP011, is a tri-specific antibody targeting DLL3, CD3, and 4-1BB for malignancies like small-cell lung cancer and neuroendocrine tumors. A Phase I/II clinical trial for EXP011 began in October 2025. A second program, EXP012, is a trispecific antibody for gastrointestinal cancers.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2026 | $28M | $111M | Apricot Capital · 5Y Capital · Eisai Innovation · Lilly Asia Ventures | ↗ |
Growth signals
Latest recorded traffic for Aikelian Biotechnology is 40 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Aikelian Biotechnology in the Jing'an District ecosystem
The Aikelian Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Matrix Partners China
Centurium Capital
Apricot Capital
5Y Capital
Eisai Innovation
Lilly Asia Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aikelian Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aikelian Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








